NASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis $3.96 +0.10 (+2.59%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.80▼$3.9650-Day Range$3.76▼$5.3552-Week Range$2.88▼$8.85Volume3,756 shsAverage Volume20,334 shsMarket Capitalization$21.50 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Aprea Therapeutics alerts: Email Address Aprea Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside291.4% Upside$15.50 Price TargetShort InterestHealthy0.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.57) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 starsMedical Sector307th out of 936 stocksPharmaceutical Preparations Industry143rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.43% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 6.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APRE. Previous Next 3.4 News and Social Media Coverage News SentimentAprea Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aprea Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for APRE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.80% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.57) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aprea Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Aprea Therapeutics Stock (NASDAQ:APRE)Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Read More APRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APRE Stock News HeadlinesJuly 17, 2024 | americanbankingnews.comHead to Head Survey: Vivesto (OTCMKTS:OASMY) vs. Aprea Therapeutics (NASDAQ:APRE)June 21, 2024 | globenewswire.comAprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024July 27, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…June 17, 2024 | globenewswire.comAprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051May 29, 2024 | msn.comAprea Therapeutics Advances Cancer Treatment Trial to Higher Dose LevelMay 28, 2024 | globenewswire.comAprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 15, 2024 | msn.comAprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug TrialsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics’ Financial and Clinical ProgressJuly 27, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…May 14, 2024 | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business UpdateMay 13, 2024 | globenewswire.comAprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | markets.businessinsider.comAprea Therapeutics Appoints Mirza As CMOMay 2, 2024 | finance.yahoo.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.April 26, 2024 | finance.yahoo.comInterim Report - January-March 2024April 12, 2024 | markets.businessinsider.comAprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy RatingApril 10, 2024 | globenewswire.comAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024See More Headlines Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APRE CUSIPN/A CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+291.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net Margins-1,317.82% Pretax Margin-1,317.82% Return on Equity-56.78% Return on Assets-46.12% Debt Debt-to-Equity RatioN/A Current Ratio11.15 Quick Ratio11.15 Sales & Book Value Annual Sales$580,000.00 Price / Sales37.07 Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book0.87Miscellaneous Outstanding Shares5,430,000Free Float4,735,000Market Cap$21.50 million OptionableNo Data Beta1.04 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Oren Gilad Ph.D. (Age 56)Co-Founder, CEO, President & Director Comp: $796.95kMr. John P. Hamill CPA (Age 60)Senior VP, CFO, Principal Accounting Officer & Secretary Comp: $610.23kDr. Dansu Li Ph.D.Head of TechnologyDr. Lars B. Abrahmsen Ph.D. (Age 67)Senior VP & Chief Scientific Officer Mr. Brian Wiley (Age 56)Senior Vice President of Corporate Development & Strategy Dr. Michel Afargan Ph.D.Head of Pharmacology DevelopmentMr. Ze'ev Weiss B.Sc. (Age 62)C.P.A., Chief Business Advisor Dr. Nadeem Q. Mirza M.D.M.P.H., Chief Medical OfficerMs. Andrea EpsteinControllerMore ExecutivesKey CompetitorsForte BiosciencesNASDAQ:FBRXCASI PharmaceuticalsNASDAQ:CASIClearside BiomedicalNASDAQ:CLSDInflaRxNASDAQ:IFRXBenitec BiopharmaNASDAQ:BNTCView All CompetitorsInsidersOren GiladBought 2,000 shares on 3/13/2024Total: $14,580.00 ($7.29/share)Bernd R SeizingerBought 6,860 shares on 3/13/2024Total: $50,009.40 ($7.29/share)John P HamillBought 1,010 shares on 3/13/2024Total: $7,362.90 ($7.29/share)View All Insider Transactions APRE Stock Analysis - Frequently Asked Questions How have APRE shares performed this year? Aprea Therapeutics' stock was trading at $4.70 on January 1st, 2024. Since then, APRE stock has decreased by 15.7% and is now trading at $3.96. View the best growth stocks for 2024 here. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.11. The business had revenue of $0.38 million for the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative trailing twelve-month return on equity of 56.78%. When did Aprea Therapeutics' stock split? Aprea Therapeutics's stock reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. Who are Aprea Therapeutics' major shareholders? Top institutional shareholders of Aprea Therapeutics include Concourse Financial Group Securities Inc.. Insiders that own company stock include Oren Gilad, Bernd R Seizinger, John P Hamill, Lars B Abrahmsen, Gregory Alan Korbel and Eyal C Attar. View institutional ownership trends. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC) and Alkermes (ALKS). This page (NASDAQ:APRE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
